Shinji Atagi

7.7k total citations · 1 hit paper
182 papers, 4.5k citations indexed

About

Shinji Atagi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Shinji Atagi has authored 182 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 155 papers in Pulmonary and Respiratory Medicine, 130 papers in Oncology and 24 papers in Surgery. Recurrent topics in Shinji Atagi's work include Lung Cancer Treatments and Mutations (128 papers), Lung Cancer Diagnosis and Treatment (68 papers) and Lung Cancer Research Studies (66 papers). Shinji Atagi is often cited by papers focused on Lung Cancer Treatments and Mutations (128 papers), Lung Cancer Diagnosis and Treatment (68 papers) and Lung Cancer Research Studies (66 papers). Shinji Atagi collaborates with scholars based in Japan, United States and Germany. Shinji Atagi's co-authors include Nobuyuki Yamamoto, Akihiro Tamiya, Kazuhiko Nakagawa, Kyoichi Okishio, Noboru Yamamoto, Toyoaki Hida, Yoshihiko Taniguchi, Kōichi Goto, Takashi Seto and Motohiro Tamiya and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Shinji Atagi

175 papers receiving 4.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

2014 561 citations Takashi Seto, Terufumi Kato et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shinji Atagi Japan	36	3.3k	3.2k	819	491	430	182	4.5k
Kathryn A. Gold United States	29	1.8k 0.6×	2.1k 0.7×	922 1.1×	448 0.9×	463 1.1×	99	3.5k
Hiroaki Akamatsu Japan	28	3.8k 1.1×	3.5k 1.1×	1.2k 1.5×	309 0.6×	1.1k 2.5×	144	5.1k
Koichi Minato Japan	29	1.6k 0.5×	2.1k 0.6×	781 1.0×	252 0.5×	364 0.8×	171	3.1k
Young Hak Kim Japan	30	1.7k 0.5×	1.9k 0.6×	644 0.8×	292 0.6×	279 0.6×	127	2.8k
Akira Ono Japan	29	1.9k 0.6×	1.7k 0.5×	388 0.5×	423 0.9×	393 0.9×	183	2.9k
Hidehito Horinouchi Japan	32	1.7k 0.5×	2.0k 0.6×	497 0.6×	271 0.6×	309 0.7×	225	3.0k
Motoki Yano Japan	34	2.0k 0.6×	1.2k 0.4×	1.1k 1.4×	403 0.8×	538 1.3×	170	3.7k
D. Johnston Canada	15	3.6k 1.1×	3.5k 1.1×	1.1k 1.4×	202 0.4×	664 1.5×	23	5.1k
Conor Steuer United States	27	1.4k 0.4×	1.4k 0.4×	797 1.0×	239 0.5×	512 1.2×	121	2.8k
Felice Pasini Italy	35	1.5k 0.5×	1.6k 0.5×	751 0.9×	544 1.1×	476 1.1×	119	3.5k

Countries citing papers authored by Shinji Atagi

Since Specialization

Citations

This map shows the geographic impact of Shinji Atagi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shinji Atagi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shinji Atagi more than expected).

Fields of papers citing papers by Shinji Atagi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shinji Atagi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shinji Atagi. The network helps show where Shinji Atagi may publish in the future.

Co-authorship network of co-authors of Shinji Atagi

This figure shows the co-authorship network connecting the top 25 collaborators of Shinji Atagi. A scholar is included among the top collaborators of Shinji Atagi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shinji Atagi. Shinji Atagi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tsuboi, Masahiro, Haruyasu Murakami, Hideyuki Harada, et al.. (2024). Treatment patterns and clinical outcomes of resectable clinical stage III non‐small cell lung cancer in a Japanese real‐world setting: Surgery cohort analysis of the SOLUTION study. Thoracic Cancer. 15(20). 1541–1552. 1 indexed citations

Kojima, Kensuke, et al.. (2024). Impact of the number of dissected lymph nodes on machine learning-based prediction of postoperative lung cancer recurrence: a single-hospital retrospective cohort study. BMJ Open Respiratory Research. 11(1). e001926–e001926.

Atagi, Shinji, Takashi Daimon, Kyoichi Okishio, et al.. (2023). A randomized phase III study of docetaxel alone versus docetaxel plus S‐1 in patients with previously treated non‐small cell lung cancer: JMTO LC09‐01. Thoracic Cancer. 14(29). 2941–2949. 1 indexed citations

Nishio, Makoto, Shinji Atagi, Kōichi Goto, et al.. (2023). Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR+ non-small-cell lung cancer. Translational Lung Cancer Research. 12(6). 1167–1184. 3 indexed citations

Shimokawa, Mototsugu, Masaki Kanazu, Ryusei Saito, et al.. (2023). Clinical benefit of platinum doublet combination therapy in older adults with advanced non‐small cell lung cancer: A prospective multicenter study by the National Hospital Organization in Japan. Thoracic Cancer. 14(17). 1597–1605. 1 indexed citations

Naito, Tateaki, Junji Uchino, Toru Kojima, et al.. (2022). A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in patients with cancer cachexia and low body mass index. Cancer. 128(10). 2025–2035. 31 indexed citations

Matsumoto, Kinnosuke, Akihiro Tamiya, Yuji Inagaki, et al.. (2021). Efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer: A multicenter retrospective cohort study. Journal of Geriatric Oncology. 13(2). 207–213. 4 indexed citations

Horinouchi, Hidehito, Shinji Atagi, Satoshi Oizumi, et al.. (2020). Real‐world outcomes of chemoradiotherapy for unresectable Stage III non‐small cell lung cancer: The SOLUTION study. Cancer Medicine. 9(18). 6597–6608. 31 indexed citations

Kogure, Yoshihito, Hideo Saka, Yuichi Takiguchi, et al.. (2018). A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol. Clinical Lung Cancer. 19(5). e711–e715. 8 indexed citations

10.

Otsubo, Kohei, Junji Kishimoto, Hirotsugu Kenmotsu, et al.. (2017). Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non–Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis. Clinical Lung Cancer. 19(1). e5–e9. 35 indexed citations

11.

Taniguchi, Yoshihiko, N. Saijo, Akihiro Tamiya, et al.. (2017). The efficacy of a reduced dose (40mg) of osimertinib with T790M-positive advanced non-small-cell lung cancer. Annals of Oncology. 28. x130–x130. 6 indexed citations

12.

Morimoto, Masahiro, Kyoichi Okishio, Masanori Akira, et al.. (2016). Duration of Twice-Daily Thoracic Radiotherapy and Time From the Start of Any Treatment to the End of Chest Irradiation as Significant Predictors of Outcomes in Limited-Disease Small-Cell Lung Cancer. Clinical Lung Cancer. 18(2). e117–e127. 4 indexed citations

13.

Murakami, Haruyasu, Nobuyuki Yamamoto, Taro Shibata, et al.. (2014). A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). Lung Cancer. 84(1). 67–72. 53 indexed citations

14.

Asami, Kazuhiro, Masaaki Kawahara, Tomonori Hirashima, et al.. (2014). Prospective phase II study of cisplatin plus pemetrexed with maintenance of pemetrexed for advanced non‐squamous cell non‐small cell lung cancer in Japan. Thoracic Cancer. 5(4). 289–296. 2 indexed citations

15.

Seto, Takashi, Terufumi Kato, Makoto Nishio, et al.. (2014). Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. The Lancet Oncology. 15(11). 1236–1244. 561 indexed citations breakdown →

16.

Kawahara, Masaaki, Shinji Atagi, Kiyoshi Komuta, et al.. (2013). Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer.. PubMed. 33(10). 4631–7. 6 indexed citations

17.

Tamiya, Akihiro, Motohiro Tamiya, Takayuki Shiroyama, et al.. (2012). Dose escalation study of carboplatin–pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. Annals of Oncology. 24(4). 980–985. 22 indexed citations

18.

Atagi, Shinji, Mutsuto Kawahara, Akihito Kubo, et al.. (2007). P2-229: Phase II study of docetaxel and S-1 combination therapy in patients with previously treated non-small-cell lung cancer. Journal of Thoracic Oncology. 2(8). S663–S663. 1 indexed citations

19.

Inoue, Yumiko, et al.. (2000). Role of Nurses in Offering Informed Consent to Clinical Trials for Advanced Lung Cancer.. Haigan. 40(7). 719–723. 1 indexed citations

20.

Atagi, Shinji, et al.. (1992). Inhibition by Fibrin Coagulation of Lung Cancer Cell Destruction by Human Interleukin‐2‐activated Killer Cells. Japanese Journal of Cancer Research. 83(10). 1088–1094. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact